December 1989 in “Inpharma (Balgowlah)” Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.
42 citations
,
January 1998 in “BioDrugs” Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.
14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
July 2025 in “Scientific Reports” Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
9 citations
,
January 2023 in “Journal of Cutaneous Immunology and Allergy” A woman's hair mostly regrew after hair loss from the COVID-19 vaccine with treatment.
18 citations
,
August 1985 in “European journal of endocrinology” Cyproterone acetate is effective for treating hirsutism, but some patients may feel worse on low-dose maintenance therapy.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
14 citations
,
May 2019 in “Human gene therapy” MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
April 2018 in “Journal of Investigative Dermatology” A new treatment using AGED to modulate PPAR-γ shows promise for treating scarring hair loss by protecting and repairing hair follicle cells.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
28 citations
,
September 2021 in “JAAD Case Reports” The Pfizer COVID-19 vaccine may rarely trigger nail psoriasis.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” Targeting the AhR pathway may help treat alopecia areata.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
September 2020 in “Acta Scientific Cancer Biology” Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
June 2022 in “International Journal of Research in Dermatology” Injectable platelet-rich fibrin is a safe and effective treatment for hair loss.
2 citations
,
April 2024 in “Journal of International Medical Research” Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.
4 citations
,
September 2019 in “Biomedical Papers/Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc Czech Republic” CD2 might be a new treatment target for patchy alopecia areata.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.